Empagliflozin as monotherapy or add-on therapy in South Asian patients with Type 2 diabetes: post hoc analysis of pooled data from four phase III trials

被引：0
|
作者：
Khunti, K. [1 ]
Asaro-Harris, A. [2 ]
Spencer, W. [3 ]
Pfarr, E. [4 ]
Naderali, E. [2 ]
Salsali, A. [5 ]
Hach, T. [4 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Eli Lilly & Co, Basingstoke, Hants, England
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P217
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [11] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
    Kohler, Sven
    Zeller, Cordula
    Iliev, Hristo
    Kaspers, Stefan
    ADVANCES IN THERAPY, 2017, 34 (07) : 1707 - 1726
  • [12] Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1773 - 1788
  • [13] Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with Type 2 diabetes: pooled data from four randomised, placebo-controlled phase III trials
    Hach, T.
    Gerich, J.
    Salsali, A.
    Kim, G.
    Hantel, S.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 64 - 65
  • [14] Urinary tract infections and genital infections in patients with Type 2 diabetes treated with empagliflozin: pooled data from four randomised, placebo-controlled phase III trials
    Kim, G.
    Gerich, J.
    Salsali, A.
    Hach, T.
    Hantel, S.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 65 - 65
  • [15] Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
    Jabbour, Serge
    Seufert, Jochen
    Scheen, Andre
    Bailey, Clifford J.
    Karup, Cathrina
    Langkilde, Anna M.
    DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 620 - 628
  • [16] Dapagliflozin as Add-On Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin
    Yang, Wenying
    Ma, Jianhua
    Li, Yiming
    Li, Yanbing
    Zhou, Zhiguang
    Kim, Jae Hyeon
    Zhao, June
    Ptaszynska, Agata
    DIABETES, 2017, 66 : A338 - A338
  • [17] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Silvina Gallo
    Roberto A. Calle
    Steven G. Terra
    Annpey Pong
    Lisa Tarasenko
    Annaswamy Raji
    Diabetes Therapy, 2020, 11 : 1849 - 1860
  • [18] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Gallo, Silvina
    Calle, Roberto A.
    Terra, Steven G.
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    DIABETES THERAPY, 2020, 11 (08) : 1849 - 1860
  • [19] Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy
    Kadowaki T.
    Tajima N.
    Odawara M.
    Minamide T.
    Kawashima M.
    Yanagida D.
    Okamoto T.
    Arjona Ferreira J.C.
    Diabetology International, 2013, 4 (3) : 160 - 172
  • [20] Safety and tolerability of atogepant: A post hoc analysis of pooled data from four clinical trials
    Rizzoli, P.
    Marmura, M. J.
    Robblee, J.
    McVige, J. W.
    Sacco, S. E.
    Ferreira, R.
    Rekeda, L.
    Ma, J.
    Dabruzzo, B. L.
    Ashina, M.
    HEADACHE, 2022, 62 : 121 - 122
12345